X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (72) 72
female (55) 55
male (55) 55
middle aged (54) 54
adult (52) 52
index medicus (48) 48
hematology (47) 47
aged (35) 35
oncology (33) 33
treatment outcome (33) 33
remission induction (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (26) 26
cancer (22) 22
chemotherapy (22) 22
leukemia, myeloid, acute - drug therapy (21) 21
life sciences (21) 21
adolescent (20) 20
acute myeloid-leukemia (19) 19
young adult (18) 18
retrospective studies (17) 17
leukemia, myeloid, acute - mortality (16) 16
prognosis (16) 16
risk factors (15) 15
aged, 80 and over (14) 14
aml (14) 14
recurrence (14) 14
disease-free survival (13) 13
leukemia (13) 13
cytarabine - administration & dosage (12) 12
leukemia, myeloid, acute - genetics (12) 12
transplantation (12) 12
acute myelogenous leukemia (11) 11
hematology, oncology and palliative medicine (11) 11
bone-marrow-transplantation (10) 10
older patients (10) 10
prospective studies (10) 10
therapy (10) 10
transplantation, homologous (10) 10
abridged index medicus (9) 9
acute disease (9) 9
acute myeloid leukemia (9) 9
cytarabine (9) 9
remission (9) 9
stem cells (9) 9
survival analysis (9) 9
trial (9) 9
antineoplastic combined chemotherapy protocols (8) 8
hematopoietic stem cell transplantation (8) 8
incidence (8) 8
randomized-trial (8) 8
relapse (8) 8
survival (8) 8
[sdv.can]life sciences [q-bio]/cancer (7) 7
adults (7) 7
hematopoietic stem cell transplantation - adverse effects (7) 7
high-dose cytarabine (7) 7
immunology (7) 7
kaplan-meier estimate (7) 7
leukemia, myeloid, acute - pathology (7) 7
mutation (7) 7
myelodysplastic syndrome (7) 7
stem cell transplantation (7) 7
survival rate (7) 7
time factors (7) 7
trans-retinoic acid (7) 7
transplantation, autologous (7) 7
[ sdv.can ] life sciences [q-bio]/cancer (6) 6
adult patients (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
child (6) 6
daunorubicin (6) 6
daunorubicin - administration & dosage (6) 6
diagnosis (6) 6
follow-up studies (6) 6
hemic and lymphatic diseases (6) 6
intensive chemotherapy (6) 6
leukemia, myeloid, acute - therapy (6) 6
leukemia, promyelocytic, acute - drug therapy (6) 6
multicenter studies as topic (6) 6
multivariate analysis (6) 6
postremission therapy (6) 6
research (6) 6
stem-cell transplantation (6) 6
usage (6) 6
1st complete remission (5) 5
age factors (5) 5
analysis (5) 5
bone marrow transplantation (5) 5
combined modality therapy (5) 5
cytarabine - therapeutic use (5) 5
hematopoietic stem cell transplantation - methods (5) 5
human health and pathology (5) 5
induction chemotherapy (5) 5
leukemia, myeloid, acute (5) 5
leukemia, myeloid, acute - diagnosis (5) 5
mesh: female (5) 5
mesh: humans (5) 5
mesh: male (5) 5
mesh: middle aged (5) 5
minimal residual disease (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal de Mycologie Medicale, ISSN 1156-5233, 09/2017, Volume 27, Issue 3, p. e9
Les infections fongiques invasives (IFI) en hematologie restent redoutables avec une mortalite elevee. Celles-ci concernent essentiellement le patient... 
Mycoses | Fluconazole
Journal Article
Journal de Mycologie Médicale, ISSN 1156-5233, 09/2017, Volume 27, Issue 3, pp. e9 - e9
Journal Article
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, ISSN 1422-0067, 07/2019, Volume 20, Issue 14, p. 3429
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1025 - 1036
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 25, pp. 2386 - 2398
Among patients with IDH1 -mutated relapsed or refractory leukemia, daily oral ivosidenib, an IDH1 inhibitor, induced molecular clearance of leukemic cells from... 
MEDICINE, GENERAL & INTERNAL | IDH2 MUTATIONS | METAANALYSIS | ACUTE MYELOID-LEUKEMIA | PROGNOSTIC-SIGNIFICANCE | DIFFERENTIATION | INHIBITOR | Glycine - analogs & derivatives | Recurrence | Follow-Up Studies | Glycine - adverse effects | Cell Count | Humans | Middle Aged | Pyridines - pharmacokinetics | Drug Resistance, Neoplasm | Male | Isocitrate Dehydrogenase - antagonists & inhibitors | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Young Adult | Pyridines - adverse effects | Enzyme Inhibitors - pharmacokinetics | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Glycine - administration & dosage | Enzyme Inhibitors - adverse effects | Glycine - pharmacokinetics | Pyridines - administration & dosage | Administration, Oral | Isocitrate Dehydrogenase - genetics | Survival Rate | Remission Induction | Leukemia, Myeloid, Acute - mortality | Adolescent | Aged | Mutation | Hemoglobins - analysis | Leukemia, Myeloid, Acute - genetics | Usage | Myelocytic leukemia | Gene mutations | Physiological aspects | Genetic aspects | Nonlymphoid leukemia | Research | Drug therapy | Isocitrate dehydrogenase | Risk factors | Thrombocytopenia | Myeloid leukemia | Leukemia | FDA approval | Cancer therapies | Patients | Investigations | Leukocytosis | Collaboration | Point mutation | Remission | Acute myeloid leukemia | Drug dosages | Neutropenia | Tumors
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2019, Volume 185, Issue 3, pp. 398 - 398
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 02/2015, Volume 125, Issue 9, pp. 1367 - 1376
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1332 - 1332
INTRODUCTION: The incidence of AML in the United States has steadily increased over the last decade and, in 2019, it is estimated AML will affect 21,450 new... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 3850 - 3850
INTRODUCTION: Standard chemotherapy regimens for AML are not effective in many patients (pts), necessitating the use of targeted therapies. FMS-like tyrosine... 
Journal Article
HAEMATOLOGICA, ISSN 0390-6078, 09/2019, Volume 104, Issue 10, pp. 2017 - 2027
Internal tandem duplication in Fms-like tyrosine kinase 3 (FLT3-ITD) is the most frequent mutation observed in acute myeloid leukemia (AML) and correlates with... 
AML | TYROSINE KINASE AXL | INTERNAL TANDEM DUPLICATION | CELLS | ACTIVATION | INHIBITION | BONE-MARROW | THERAPEUTIC TARGET | HEMATOLOGY | EXPRESSION | RECEPTOR-ALPHA | Life Sciences | Human health and pathology | Hematology | Cellular Biology | Cell Behavior | Cancer
Journal Article
Haematologica, ISSN 0390-6078, 10/2010, Volume 95, Issue 10, pp. 1762 - 1768
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2006, Volume 24, Issue 36, pp. 5703 - 5710
Journal Article
Journal Article